Targeting in Cancer Therapies
1
Biomedical Research Institute Sant Pau (IIB-SantPau) and Josep Carreras Leukemia Research Institute, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain
2
CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Bellaterra, 08193 Cerdanyola del Vallès, Spain
3
Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, 08193 Cerdanyola del Vallès, Spain
4
Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, 08193 Cerdanyola del Vallès, Spain
*
Author to whom correspondence should be addressed.
Academic Editor: Yu-Jia Chang
Med. Sci. 2016, 4(1), 6; https://doi.org/10.3390/medsci4010006
Received: 2 March 2016
/
Revised: 2 March 2016
/
Accepted: 3 March 2016
/
Published: 8 March 2016
Note: In lieu of an abstract, this is an excerpt from the first page.
Drug developers recruit and combine principles, procedures and strategies from chemistry, pharmacology, nanotechnology and biotechnology, focusing on the generation of functional vehicles as nano-carriers of drugs for improved stability and enhanced intracellular delivery.[...] View Full-Text
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Mangues, R.; Vázquez, E.; Villaverde, A. Targeting in Cancer Therapies. Med. Sci. 2016, 4, 6. https://doi.org/10.3390/medsci4010006
AMA Style
Mangues R, Vázquez E, Villaverde A. Targeting in Cancer Therapies. Medical Sciences. 2016; 4(1):6. https://doi.org/10.3390/medsci4010006
Chicago/Turabian StyleMangues, Ramon, Esther Vázquez, and Antonio Villaverde. 2016. "Targeting in Cancer Therapies" Medical Sciences 4, no. 1: 6. https://doi.org/10.3390/medsci4010006
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
